About Oyster Point

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.

Our lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptors (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED). Dry eye disease is a multifactorial chronic disease of the ocular surface characterized by a loss of homeostasis of the tear film, resulting in pain, visual impairment, tear film hyperosmolarity and instability, inflammation and corneal wounding. More than 340 million adults globally and approximately 34 million adults in the United States are estimated to suffer from DED.

OC-01’s novel mechanism of action is designed to re-establish tear film homeostasis by activating the trigeminal parasympathetic pathway and stimulating the glands and cells responsible for natural tear film production. Human tear film is a complex mixture of more than 1,500 different proteins, including antibodies and numerous classes of lipids and mucins that are responsible for forming the primary refracting surface of the cornea, as well as protecting and moisturizing the cornea. The Lacrimal Functional Unit (LFU), which is controlled by the parasympathetic nervous system, is comprised of glands and cells responsible for producing the three layers that comprise healthy tear film. To stimulate the LFU, we are targeting a class of receptors called nicotinic acetylcholine receptors (nAChR) that are located on the trigeminal nerve and readily accessible within the anterior nasal cavity. We plan to leverage our nAChR domain expertise to disrupt how ocular surface diseases are currently treated.

Leadership

Our team knows eye care—we have assembled a team with extensive experience developing and commercializing leading ophthalmic products and therapies.

Jeffrey Nau, PhD, MMS

President and Chief Executive Officer

Jeff has built his career on developing novel, innovative therapies for diseases of the eye, with over 15 years of experience working with biotechnology, pharmaceutical, and medical device companies. Most recently, he was VP, Clinical and Medical Affairs, at Ophthotech. Prior to that, Jeff was a Medical Science Director at Genentech working on the development of Lucentis®, a transformative drug for retinal diseases. Jeff has helped raise more than $250 million in equity for innovative startups such as Genaera Corporation, Acuity Pharmaceuticals, and NeoVista, Inc. He holds numerous patents and peer-reviewed publications. Jeff has a Ph.D. in Public Health and Epidemiology from Walden University, a Master’s in Medial Science from MCP Hahnemann School of Medicine, and a B.S. in Biology from Stony Brook University.

Daniel Lochner, MBA

Chief Financial Officer

Daniel has nearly 15 years of experience in healthcare investing. Prior to joining Oyster Point Pharma, Daniel held positions of increasing responsibility in equity investing and fund management at Goldman Sachs Asset Management. Most recently he was a Managing Director and Portfolio Manager at Goldman Sachs, where he was a healthcare equity investor for various fund strategies. As a healthcare investor, Daniel focused on biotechnology, pharmaceutical, medical device and healthcare services companies and invested in a range of therapeutic categories, including ophthalmology. Daniel received an Executive M.B.A. from Columbia University in 2011 and a B.A. in Economics from the University of Richmond in 2005.

John Snisarenko, MBA

John Snisarenko, MBA

Chief Commercial Officer

John has 30 years of commercial experience in the pharmaceutical industry, including major ophthalmology businesses. He has a proven track record in taking programs from development to successful commercialization, and helping businesses achieve high growth. Prior to joining Oyster Point, John spent the past 2 years at Shire (now Takeda) as Group Vice President and Head of its ophthalmic business. During that time, he led a large, multidisciplinary team accountable for the growth of Shire’s first ophthalmic therapeutic, Xiidra ®, for treatment of dry eye. He served as a member of the commercial leadership team at Shire and played a key role in the divestiture of the ophthalmic business to Novartis Pharma. Prior to joining Shire, John led commercial activities for Genentech’s ophthalmology (Lucentis ®) and rheumatology (Rituxan ®, Actemra ®) franchises for 10 years. John has also held various positions of increasing responsibility at CIBA Vision/Novartis Pharma. He holds a B.Sc. in Biochemistry and an MBA in Marketing and International Business from McGill University in Montreal, Canada.

Loni Da Silva, MS, RAC

Vice President of Regulatory Affairs

Loni has over 30 years of leadership experience in global regulatory affairs and strategic drug development, with more than 20 years in the ophthalmic space. She began her career at Hoffman La-Roche, and most recently served as SVP, Global Regulatory Affairs for Ophthotech, where she worked on wet and dry AMD. Loni has led global regulatory affairs for 3 start-ups and IPOs including Eyetech, Pharmasset, and Ophthotech. In addition to ophthalmics, her experience also includes oncology, antivirals, anti-infectives, hematology, pain management, and cardiology. Loni received her B.S. in microbiology from Penn State University and a M.S. in regulatory affairs from Long Island University.

Dawn Pruitt Koffler, MBA

Vice President of Marketing

Dawn has over 15 years of experience in sales and marketing for pharmaceutical products and medical devices. Prior to joining Oyster Point, she spent 12 years at Allergan where she served as Executive Director for consumer eye care, which included the TrueTear® device and Refresh® brands. Before that, Dawn was Executive Director of Strategic Marketing, responsible for leading the commercial strategy for the eye care pipeline, and led consumer marketing for Restasis®, which earned her recognition as a Top 25 DTC marketer. She was also a member of the Global Eye Care R&D Governance Board and was the commercial lead for the integration of Oculeve and ForSight VISION5. Dawn holds a B.S. in physical therapy from California State University, Long Beach and an M.B.A. from the University of Notre Dame.

George Donato, MBA

Vice President of CMC

George is an accomplished Pharmaceutical Operations and Technical CMC executive with over 25 years delivering exceptional results in new product launches, product development and supply chain. Most recently he was the Sr. Vice President, Global Operations for Iroko Pharmaceuticals and prior to that he was a New Product Leader at Pfizer. He has successfully launched several new products globally for Iroko, Pfizer and Wyeth. George is adept at balancing regulatory, quality, technical, supply and commercial needs to continuously improve process performance, quality and profitability. George graduated from Widener University with an M.B.A. and a B.S. in Engineering.

Board of Directors

MICHAEL ACKERMANN, PhD

Chairman of the Board

Michael currently serves as the Chairman of the Board. Michael is also developing two additional early-stage healthcare ventures. He was mostly recently Vice President, Neurostimulation for Allergan, plc after serving as CEO of Oculeve, Inc., which was acquired by Allergan in August 2015. He has experience in medical device and pharmaceutical development in both academic and industrial settings. He received a B.E. degree, magna cum laude, in biomedical engineering from Vanderbilt University; M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University; is a graduate of the Stanford University Biodesign Fellowship; and Vision Research Fellowship at Stanford. He has numerous patents and peer-reviewed publications.

Jeffrey Nau, PhD, MMS

President and Chief Executive Officer

Jeff has built his career on developing novel, innovative therapies for diseases of the eye, with over 15 years of experience working with biotechnology, pharmaceutical, and medical device companies. Most recently, he was VP, Clinical and Medical Affairs, at Ophthotech. Prior to that, Jeff was a Medical Science Director at Genentech working on the development of Lucentis®, a transformative drug for retinal diseases. Jeff has helped raise more than $250 million in equity for innovative startups such as Genaera Corporation, Acuity Pharmaceuticals, and NeoVista, Inc. He holds numerous patents and peer-reviewed publications. Jeff has a Ph.D. in Public Health and Epidemiology from Walden University, a Master’s in Medial Science from MCP Hahnemann School of Medicine, and a B.S. in Biology from Stony Brook University.

Mark Murray

Director

Mark has been a CFO in the life science sector for over 30 years, working with senior executives and their boards. His eye care experience includes the successful exits of Optimedica and Oculeve. Mark spent over 20 years with Guidant Corporation, where he was part of the senior management team through its $1 billion IPO until its acquisition in 2006 for $27 billion (by Boston Scientific and Abbott Labs). He has helped raise over $1.6 billion in equity and over $500 million in debt for public and private companies. Mark is currently a partner at FLG Partners, LLC. He holds a B.S. in business administration (accounting) from San Francisco State University.

Ali Behbahani, M.D.

Director

Ali joined NEA in 2007 and is a Partner on the healthcare team. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical and healthcare services sectors. Prior to joining NEA, Ali worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University. Ali concurrently earned his MD degree from The University of Pennsylvania School of Medicine and his MBA degree from The University of Pennsylvania Wharton School, where he graduated with Honors and was a Palmer Scholar. He graduated summa cum laude and received his bachelor’s degrees with distinction in Biomedical Engineering, Electrical Engineering and Chemistry from Duke University. Ali serves on the boards of directors of the following companies: Adaptimmune, Arcellx, Cardionomic, CRISPR Therapeutics, CVRx, Genocea, Ivantis, Minerva Surgical, Nevro, Nkarta, Oyster Point Pharma and Solace Therapeutics.

WILLIAM J. LINK, PhD

Director

Bill specializes early-stage investing in medical devices. He is a founder and Principal of Flying L Partners and he is a founder and Managing Director of Versant Ventures. Prior to co-founding Versant Ventures, Bill was a general partner at Brentwood Venture Capital, and has over two decades of operations experience in the healthcare industry. Bill was previously founder, chairman, and CEO of Chiron Vision, which was sold to Bausch and Lomb in 1997. Prior to Chiron Vision, Bill founded and served as President of American Medical Optics (AMO), a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later, he served on the Board of AMO’s successor company, Advanced Medical Optics (AMO) which was acquired by Abbott in 2009. AMO was acquired by Johnson and Johnson in 2016. Before entering the healthcare industry, he was an Assistant Professor in the Department of Surgery at the Indiana University School of Medicine. Bill currently serves on the board of several private companies and three public companies, Edwards Lifesciences, Glaukos, and Second Sight Medical Products. He received his B.S., M.S., and Ph.D. from Purdue University.

CLARE OZAWA, PHD

Director

Clare is a managing director at Versant Ventures with a focus on investments in San Diego and the Bay Area. Previously, Clare was COO of Inception Sciences, where she was responsible for strategic business development, operations and finance for the Inception Sciences research sites in San Diego, Vancouver and Montreal. During her tenure at Inception, she assumed leadership roles in the creation and management of six new companies launched in partnership with academic researchers and major biopharmaceutical companies.

Before joining Inception, she was an investment professional at Versant, where she was involved in several successful investments including Flexion (NASDAQ:FLXN), Biotie (purchased by Acorda), and Quanticel (purchased by Celgene). She joined Versant from Novartis Pharma, where she worked in the Office of the CEO leading strategic initiatives for the Novartis Pharma Executive Committee.

Previously, Clare was at McKinsey & Company where she advised clients across the biopharmaceutical sector. Clare earned a Bachelor of Science degree in biological sciences with honors and distinction from Stanford University, and a Ph.D. in neurosciences from Stanford University Medical School.

Benjamin Tsai

Director

Ben is a partner at Invus Opportunities, a New York based investment firm that currently manages over $1.5 billion of capital. Ben joined Invus Opportunities in 2008 when the firm spun off from sister firm The Invus Group, an equity investment firm founded in 1985 with over $8 billion of evergreen capital. Ben leads investments by Invus Opportunities in growing private companies, and works in close partnership with market-leading management teams and investors to create lasting value. Ben has served on the Board of Directors of numerous companies, both in the health care sector as well as in other industries. Prior to joining Invus Opportunities, Ben was a management consultant at the Monitor Group. Ben received a B.S. in business administration from the University of Southern California and an M.B.A. from Harvard Business School.

1Market Scope 2016 Dry Eye Products Report: A Global Market Analysis for 2015 to 2021

2Paulsen AJ, Cruickshanks KJ, Fischer ME, Huang GH, Klein BE, Klein R, Dalton DS. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. American Journal of Ophthalmology. 2014 Apr;157(4):799-806.

3 Jennifer P. Craig, MCOptom, PhD, Kelly K. Nichols, OD, PhD, Esen K. Akpek, MD, Barbara Caffery, OD, PhD, Harminder S. Dua, MD, PhD, Choun-Ki Joo, MD, PhD, Zuguo Liu, MD, PhD, J. Daniel Nelson, MD, Jason J. Nichols, OD, PhD, Kazuo Tsubota, MD, PhD, Fiona Stapleton, MCOptom, PhD. TFOS DEWS II Definition and Classification Report; / The Ocular Surface 15 (2017) 276-283